Key statistics
As of last trade Axsome Therapeutics Inc (19X:STU) traded at 152.50, -6.10% below its 52-week high of 162.40, set on Jan 22, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 152.65 |
|---|---|
| High | 156.40 |
| Low | 152.25 |
| Bid | 152.30 |
| Offer | 152.95 |
| Previous close | 154.55 |
| Average volume | 44.57 |
|---|---|
| Shares outstanding | 50.41m |
| Free float | 42.34m |
| P/E (TTM) | -- |
| Market cap | 9.14bn USD |
| EPS (TTM) | -4.67 USD |
Data delayed at least 15 minutes, as of Feb 13 2026.
More ▼
Announcements
- Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
- Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
- Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
- Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
- Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
- Axsome Therapeutics to Participate in Upcoming Investor Conferences
- Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
- Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
- Axsome Therapeutics to Participate in Upcoming Investor Conferences
- Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
More ▼
